Table 3. Kruskal-Wallace test (p < 0.05) with post-hoc pairwise analysis of HPC and CTX ERK 1/2 phosphorylation following BDNF, EGF, and/or PLX4032 treatment.
| Factor | n | Average Rank | Different (p < 0.05) from factor n |
|---|---|---|---|
| (1) CTX_BDNF | 3 | 8.33 | (7)(8)(9)(10)(11)(12) |
| (2) CTX_DMSO | 3 | 8.33 | (7)(8)(9)(10)(11)(12) |
| (3) CTX_EGF | 3 | 9 | (7)(9)(10)(11)(12) |
| (4) CTX_PLX | 3 | 5.67 | (6)(7)(8)(9)(10)(11)(12) |
| (5) CTX_PLX_BDN | 3 | 16.33 | (7)(9)(11) |
| (6) CTX_PLX_EGF | 3 | 18.67 | (4)(7) |
| (7) HPC_BDNF | 3 | 31 | (1)(2)(3)(4)(5)(6) |
| (8) HPC_DMSO | 3 | 20.67 | (1)(2)(4) |
| (9) HPC_EGF | 3 | 28.67 | (1)(2)(3)(4)(5) |
| (10) HPC_PLX | 3 | 22 | (1)(2)(3)(4) |
| (11) HPC_PLX_BDN | 3 | 29 | (1)(2)(3)(4)(5) |
| (12) HPC_PLX_EGF | 3 | 24.33 | (1)(2)(3)(4) |